Trial Profile
An Observational study to evaluated the mechanism of resistance to osimertinib in patients with advanced T790M-positive Non-small-cell-lung-cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Apr 2017
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Apr 2017 New trial record
- 05 Apr 2017 Results presented at the 108th Annual Meeting of the American Association for Cancer Research